273 related articles for article (PubMed ID: 24656965)
1. Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells.
Carrascal MA; Severino PF; Guadalupe Cabral M; Silva M; Ferreira JA; Calais F; Quinto H; Pen C; Ligeiro D; Santos LL; Dall'Olio F; Videira PA
Mol Oncol; 2014 May; 8(3):753-65. PubMed ID: 24656965
[TBL] [Abstract][Full Text] [Related]
2. Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy.
Lima L; Severino PF; Silva M; Miranda A; Tavares A; Pereira S; Fernandes E; Cruz R; Amaro T; Reis CA; Dall'Olio F; Amado F; Videira PA; Santos L; Ferreira JA
Br J Cancer; 2013 Oct; 109(8):2106-14. PubMed ID: 24064971
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours.
Ferreira JA; Videira PA; Lima L; Pereira S; Silva M; Carrascal M; Severino PF; Fernandes E; Almeida A; Costa C; Vitorino R; Amaro T; Oliveira MJ; Reis CA; Dall'Olio F; Amado F; Santos LL
Mol Oncol; 2013 Jun; 7(3):719-31. PubMed ID: 23567325
[TBL] [Abstract][Full Text] [Related]
4. Delivery of alloantigens via apoptotic cells generates dendritic cells with an immature tolerogenic phenotype.
Gleisner MA; Rosemblatt M; Fierro JA; Bono MR
Transplant Proc; 2011; 43(6):2325-33. PubMed ID: 21839264
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of cisplatin resistant bladder tumor by combination of cisplatin treatment and co-culture of dendritic cells with apoptotic bladder cancer cells.
Zhang Q; Chen Z
Cell Mol Biol (Noisy-le-grand); 2018 Jul; 64(10):102-107. PubMed ID: 30084800
[TBL] [Abstract][Full Text] [Related]
6. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
Kalady MF; Onaitis MW; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
J Surg Res; 2004 Jan; 116(1):24-31. PubMed ID: 14732346
[TBL] [Abstract][Full Text] [Related]
7. Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases.
Lima L; Neves M; Oliveira MI; Dieguez L; Freitas R; Azevedo R; Gaiteiro C; Soares J; Ferreira D; Peixoto A; Fernandes E; Montezuma D; Tavares A; Ribeiro R; Castro A; Oliveira M; Fraga A; Reis CA; Santos LL; Ferreira JA
Urol Oncol; 2017 Dec; 35(12):675.e1-675.e8. PubMed ID: 28911924
[TBL] [Abstract][Full Text] [Related]
8. Modification of anti-tumor immunity by tolerogenic dendritic cells.
Chen L; Hasni MS; Jondal M; Yakimchuk K
Autoimmunity; 2017 Sep; 50(6):370-376. PubMed ID: 28675711
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
Kim WS; Kim H; Kwon KW; Im SH; Lee BR; Ha SJ; Shin SJ
Oncotarget; 2016 Jun; 7(23):33765-82. PubMed ID: 27172902
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension.
Peixoto A; Fernandes E; Gaiteiro C; Lima L; Azevedo R; Soares J; Cotton S; Parreira B; Neves M; Amaro T; Tavares A; Teixeira F; Palmeira C; Rangel M; Silva AM; Reis CA; Santos LL; Oliveira MJ; Ferreira JA
Oncotarget; 2016 Sep; 7(39):63138-63157. PubMed ID: 27542232
[TBL] [Abstract][Full Text] [Related]
11. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.
Sandmaier BM; Oparin DV; Holmberg LA; Reddish MA; MacLean GD; Longenecker BM
J Immunother; 1999 Jan; 22(1):54-66. PubMed ID: 9924700
[TBL] [Abstract][Full Text] [Related]
12. Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acids.
Loureiro LR; Sousa DP; Ferreira D; Chai W; Lima L; Pereira C; Lopes CB; Correia VG; Silva LM; Li C; Santos LL; Ferreira JA; Barbas A; Palma AS; Novo C; Videira PA
Sci Rep; 2018 Aug; 8(1):12196. PubMed ID: 30111774
[TBL] [Abstract][Full Text] [Related]
13. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
15. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails.
Jongmans W; Tiemessen DM; van Vlodrop IJ; Mulders PF; Oosterwijk E
J Immunother; 2005; 28(5):480-7. PubMed ID: 16113604
[TBL] [Abstract][Full Text] [Related]
16. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response.
Osada T; Nagawa H; Takahashi T; Tsuno NH; Kitayama J; Shibata Y
J Immunother; 2002; 25(2):176-84. PubMed ID: 12074047
[TBL] [Abstract][Full Text] [Related]
18. Selective depletion of CD11c
Wang L; Li Z; Ciric B; Safavi F; Zhang GX; Rostami A
Eur J Immunol; 2016 Oct; 46(10):2454-2466. PubMed ID: 27338697
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived immuno-modulators induce overlapping pro-tolerogenic gene expression signatures in human dendritic cells.
Trojandt S; Bellinghausen I; Reske-Kunz AB; Bros M
Hum Immunol; 2016 Dec; 77(12):1223-1231. PubMed ID: 27593566
[TBL] [Abstract][Full Text] [Related]
20. Generation of potent cytotoxic T lymphocytes against in male patients with non-muscle invasive bladder cancer by dendritic cells loaded with dying T24 bladder cancer cells.
Hwang EC; Jung SI; Lee HJ; Lee JJ; Kwon DD
Int Braz J Urol; 2017; 43(4):615-627. PubMed ID: 28266813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
